An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia

References

• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.
   PubMed Web of Science ®Google Scholar
• Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019;38:1–9.
   PubMed Web of Science ®Google Scholar
• Cole CL, Kleckner IR, Jatoi A, et al. The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. JCSM Clin Rep. 2018; 3.
   Google Scholar
• Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia–pathophysiology and management. J Gastroenterol. 2013;48:574–594.
   PubMed Web of Science ®Google Scholar
• Fonseca GWPD, Farkas J, Dora E, et al. Cancer Cachexia and Related Metabolic Dysfunction. Int J Mol Sci. 2020;21(7):2321.
   Web of Science ®Google Scholar
• Peixoto da Silva S, Santos JMO. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J Cachexia Sarcopenia Muscle. 2020;11:619–635.
   PubMed Web of Science ®Google Scholar
• Mytelka DS, Li L, Benoit K. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2018;9:86–92.
   PubMed Web of Science ®Google Scholar
• Choi MH, Yoon SB, Lee K, et al. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9:326–334.
   PubMed Web of Science ®Google Scholar
• Daly L, Dolan R, Power D, et al. The relationship between the BMI-adjusted weight loss grading system and quality of life in patients with incurable cancer. J Cachexia Sarcopenia Muscle. 2020;11:160–168.
   PubMed Web of Science ®Google Scholar
• Hacker UT, Hasenclever D, Linder N, et al. Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle. 2020;11:135–144.
   PubMed Web of Science ®Google Scholar
• Lee J, Lin JB, Wu MH, et al. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer. J Cachexia Sarcopenia Muscle. 2019;10:814–826.
   PubMed Web of Science ®Google Scholar
• Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5:607–616.
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–497.
   PubMed Web of Science ®Google Scholar
• Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106:966–973.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563.
   PubMed Web of Science ®Google Scholar
• Anker MS, Holcomb R, Muscaritoli M, et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle. 2019;10:22–34.
   PubMed Web of Science ®Google Scholar
• Ruiz-García V, López-Briz E, Carbonell-Sanchis R, et al. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle. 2018;9:444–452.
   PubMed Web of Science ®Google Scholar
• Dev R, Wong A, Hui D, et al. The Evolving Approach to Management of Cancer Cachexia. Oncology (Williston Park). 2017;31:23–32.
   PubMed Web of Science ®Google Scholar
• Yennurajalingam S, Bruera E. Role of corticosteroids for fatigue in advanced incurable cancer: is it a ‘wonder drug’ or ‘deal with the devil’. Curr Opin Support Palliat Care. 2014;8:346–351.
   PubMed Web of Science ®Google Scholar
• Advani SM, Advani PG, VonVille HM, et al. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. BMC Cancer. 2018;18:1174.
   PubMed Web of Science ®Google Scholar
• Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer. 2012;118:4785–4794.
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2832–2836.
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–531.
   PubMed Web of Science ®Google Scholar
• Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016;24:3495–3505.
   PubMed Web of Science ®Google Scholar
• Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124:606–616.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer. 2013;21:129–137.
   PubMed Web of Science ®Google Scholar
• Northrup R, Kuroda K, Duus E, et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer. 2013;21:2409–2415.
   PubMed Web of Science ®Google Scholar
• Khatib MN, Gaidhane A, Gaidhane S, et al. Ghrelin as a Promising Therapeutic Option for Cancer Cachexia. Cell Physiol Biochem. 2018;48:2172–2188.
   PubMedGoogle Scholar
• Castañeda TR, Tong J, Datta R, et al. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol. 2010;31:44–60.
   PubMed Web of Science ®Google Scholar
• Guillory B, Splenser A, Garcia J. The role of ghrelin in anorexia-cachexia syndromes. Vitam Horm. 2013;92:61–106.
   PubMed Web of Science ®Google Scholar
• Sohn JW. Network of hypothalamic neurons that control appetite. BMB Rep. 2015;48:229–233.
   PubMed Web of Science ®Google Scholar
• Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37:649–661.
   PubMed Web of Science ®Google Scholar
• Brown DJ, Milroy R, Preston T, et al. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol. 2007;60:705–708.
   PubMed Web of Science ®Google Scholar
• Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–913.
   PubMed Web of Science ®Google Scholar
• Fouladiun M, Körner U, Bosaeus I, et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103:2189–2198.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003;9:774–778.
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Polyzos A, Dilana KD, et al. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2009;66:393–398.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90:2920–2926.
   PubMed Web of Science ®Google Scholar
• Argilés JM, Stemmler B, López-Soriano FJ, et al. Inter-tissue communication in cancer cachexia. Nat Rev Endocrinol. 2018;15:9–20.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Rosano GMC. Cancer cachexia: an orphan with a future. J Cachexia Sarcopenia Muscle. 2019;10:3–5.
   PubMed Web of Science ®Google Scholar
• Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept. 2010;160:81–90.
   PubMed Web of Science ®Google Scholar
• Yasuda T, Masaki T, Kakuma T, et al. Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. Neurosci Lett. 2003;349:75–78.
   PubMed Web of Science ®Google Scholar
• Lundholm K, Gunnebo L, Körner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer. 2010;116:2044–2052.
   PubMed Web of Science ®Google Scholar
• PorporatoPE, Filigheddu N, Reano S, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest. 2013;123:611–622.
   PubMed Web of Science ®Google Scholar
• Filigheddu N, Gnocchi VF, Coscia M, et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell. 2007;18:986–994.
   PubMed Web of Science ®Google Scholar
• Sheriff S, Kadeer N, Joshi R, et al. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol Cell Endocrinol. 2012;351:286–295.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 2007;12:594–600.
   PubMed Web of Science ®Google Scholar
• Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149:601–611.
   PubMed Web of Science ®Google Scholar
• Campbell GA, Patrie JT, Gaylinn BD, et al. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrol Dial Transplant. 2018;33:523–530.
   PubMed Web of Science ®Google Scholar
• Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5:329–337.
   PubMed Web of Science ®Google Scholar
• Blum RA, Mair S, Duus EM. Appetite and food intake results from phase I studies of anamorelin. J Cachexia Sarcopenia Muscle. 2019;10:1027–1035.
   PubMed Web of Science ®Google Scholar
• Dc Tj C, Abernethy AP, Friend J, et al. Body weight response with anamorelin in advanced non-small cell lung
   Google Scholar
• Currow D, Temel JS, Abernethy A, et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28:1949–1956.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108–116.
   PubMed Web of Science ®Google Scholar
• Kilgour RD, Vigano A, Trutschnigg B, et al. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer. 2013;21:3261–3270.
   PubMed Web of Science ®Google Scholar
• Crawford J. What are the criteria for response to cachexia treatment? Ann Palliat Med. 2019;8:43–49.
   PubMed Web of Science ®Google Scholar
• Mitchell T, Clarke L, Goldberg A, et al. Pancreatic Cancer Cachexia: the Role of Nutritional Interventions. Healthcare (Basel). 2019;7(3):89.
   Google Scholar
• Chung HY, Park YK. Rationale, Feasibility and Acceptability of Ketogenic Diet for Cancer Treatment. J Cancer Prev. 2017;22:127–134.
   PubMed Web of Science ®Google Scholar
• Strasser B, Steindorf K, Wiskemann J, et al. Impact of resistance training in cancer survivors: a meta-banalysis. Med Sci Sports Exerc. 2013;45:2080–2090.
   PubMed Web of Science ®Google Scholar
• Cermak NM, Res PT, de Groot LC, et al. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012;96:1454–1464.
   PubMed Web of Science ®Google Scholar
• Arrieta H, Astrugue C, Regueme S, et al. Effects of a physical activity programme to prevent physical performance decline in onco-geriatric patients: a randomized multicentre trial. J Cachexia Sarcopenia Muscle. 2019;10:287–297.
   PubMed Web of Science ®Google Scholar
• Maddocks M, Jones LW, Wilcock A. Immunological and hormonal effects of exercise: implications for cancer cachexia. Curr Opin Support Palliat Care. 2013;7:376–382.
   PubMed Web of Science ®Google Scholar
• Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2015;6:208–211.
   PubMed Web of Science ®Google Scholar
• Maddocks M, Murton AJ, Wilcock A. Therapeutic exercise in cancer cachexia. Crit Rev Oncog. 2012;17:285–292.
   PubMedGoogle Scholar
• Hall CC, Cook J, Maddocks M, et al. Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review. Support Care Cancer. 2019;27:2371–2384.
   PubMed Web of Science ®Google Scholar
• Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport Exerc Med. 2016;2:e000143.
   PubMedGoogle Scholar
• Sargeant JA, Henson J, JA K, et al. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019;34:247–262.
   PubMedGoogle Scholar
• Nagai Y, Fukuda H, Kawanabe S, et al. Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy. J Clin Med Res. 2019;11:297–300.
   PubMedGoogle Scholar
• Aniort J, Stella A, Philipponnet C, et al. Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: common mechanisms at work. J Cachexia Sarcopenia Muscle. 2019;10:323–337.
   PubMed Web of Science ®Google Scholar